Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole Full Text
Investigational New Drugs, 05/10/2012
Clinical Article
Devriese LA et al. – The results indicate that eribulin mesylate can be safely co–administered with ketoconazole. Drug–drug interactions are not expected with other CYP3A4 inhibitors.



